Related Experiment Video
Updated: May 1, 2026
Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
Analysis of systemic serum vancomycin levels following intraarticular application in primary total joint arthroplasty
Stauss R1, Savov P2, Seeber Gh2,3
1School of Medicine and Health Sciences, Division of Orthopaedics at Campus Pius-Hospital, Carl von Ossietzky Universität Oldenburg, Georgstraße 12, 26121, Oldenburg, Germany. ricarda.stauss@uni-oldenburg.de.
Introduction:
Periprosthetic joint infection (PJI) is a serious complication following primary total joint arthroplasty (TJA). PJI accounts for 15-25% of revision surgeries, therefore it is associated with PJI is associated with substantial patient morbidity and mortality as well as increased healthcare expenditures due to complex treatment strategies. Recently, intraoperative local application of vancomycin powder is increasingly being used in primary total hip and knee arthroplasty (THA, TKA) as an additive strategy for PJI prevention. Whereas local vancomycin concentrations have already been investigated in prior studies, evidence on systemic vancomycin levels and potential adverse drug reactions (ADR) is limited. Purpose of this study was to investigate systemic vancomycin levels following intraarticular application in primary TJA.
Materials And Methods:
This pilot study is a prospective analysis of patients undergoing primary THA and TKA between April and July 2023. One gram of vancomycin powder was applied to the prosthesis prior to wound closure. Serum vancomycin levels were measured at two standardised time points, 24 and 48 h postoperatively.
Results:
In total, 103 patients were included, and the patient collective was further stratified by surgical procedure into a THA subgroup (n = 52) and a TKA subgroup (n = 51). Mean serum vancomycin levels showed a significant group difference at both time points (24 h: p < 0.001; 48 h: p = 0.044) with higher serum vancomycin concentrations in the THA cohort. Mean serum vancomycin levels in THA patients were 1.25 μg/ml (range 0.00-7.00 μg/ml) after 24 h and 0.34 μg/ml (range 0.00-4.80 μg/ml) 48 h postoperatively. In TKA, no systemic vancomycin levels were detected. Vancomycin concentrations did not reach therapeutic levels in any patient. No ADR was detected in the whole study collective.
Conclusion:
Following intraarticular administration of vancomycin powder, no systemic vancomycin levels within the therapeutic range were detected, thus it may serve as a safe and cost-effective adjunct to strategies for prevention of PJI.
Insights
Intraarticular vancomycin powder in primary total joint arthroplasty (TJA) did not result in systemic levels within the therapeutic range. This suggests vancomycin powder is a safe adjunct for preventing periprosthetic joint infection (PJI).
Area of Science:
- Orthopedic Surgery
- Infectious Disease Prevention
- Pharmacology
Background:
- Periprosthetic joint infection (PJI) is a severe complication of total joint arthroplasty (TJA), leading to significant morbidity, mortality, and healthcare costs.
- Intraoperative vancomycin powder is increasingly used for PJI prevention in primary total hip arthroplasty (THA) and total knee arthroplasty (TKA).
- Limited data exists on systemic vancomycin levels and adverse drug reactions (ADR) following intraarticular application.
Purpose of the Study:
- To investigate systemic vancomycin levels after intraarticular administration in primary TJA.
- To assess potential adverse drug reactions (ADR) associated with intraarticular vancomycin use.
Main Methods:
- Prospective pilot study of 103 patients undergoing primary THA or TKA.
- 1 gram of vancomycin powder applied intraarticularly before wound closure.
- Serum vancomycin levels measured at 24 and 48 hours postoperatively.
Main Results:
- Higher mean serum vancomycin levels observed in THA patients compared to TKA at 24 and 48 hours (p<0.001 and p=0.044, respectively).
- Mean THA levels: 1.25 μg/ml at 24h, 0.34 μg/ml at 48h; TKA patients had no detectable systemic levels.
- No vancomycin concentrations reached therapeutic levels, and no adverse drug reactions were reported.
Conclusions:
- Intraarticular vancomycin powder in primary TJA does not lead to significant systemic absorption.
- The findings suggest intraarticular vancomycin powder is a safe and potentially cost-effective method for PJI prevention.
- Further research may confirm its role as an adjunct in PJI prophylaxis strategies.
Related Concept Videos
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
01:26Therapeutic Drug Monitoring: Drug Analysis Methods